Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Tandem Diabetes Care (TNDM) and raises the price target from $39 to $55.
May 06, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays raises Tandem Diabetes Care's price target to $55, maintaining an Overweight rating.
The increase in price target by Barclays, accompanied by an Overweight rating, suggests a strong bullish outlook for Tandem Diabetes Care. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in TNDM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100